PGEN vs PRAX Stock Comparison

PRAX currently leads PGEN in this stock comparison, with AIQ scores of 57 vs 55. The clearest difference is risk resilience, while PGEN has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 2 points
PGEN
Healthcare
vs
PRAX
Healthcare
PGEN
Precigen, Inc.
Price
$4.54
Day move
-2.58%
AIQ Score
55/100
Best edge
Momentum
Sector
Healthcare
PRAX
Praxis Precision Medicines, Inc.
Leads
Price
$328
Day move
+1.04%
AIQ Score
57/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between PGEN and PRAX?

PRAX leads the current stock comparison as Praxis Precision Medicines, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Precigen, Inc. vs Praxis Precision Medicines, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

PRAX leads

PRAX leads by 2 AIQ points, primarily on Risk Resilience and Quality, having only recently taken the lead back from PGEN. Wall Street currently favors PGEN on target upside.

Fragile: 2 of 5 evidence groups support PRAX, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 2 of 5Comparison trend: Reversed
PGEN

Precigen, Inc.

AIQ Score
55/100
AIQ Edge Score
5/10
PRAX

Praxis Precision Medicines, Inc.

Leads
AIQ Score
57/100
AIQ Edge Score
9/10

The Algovestiq AIQ Score currently favors PRAX over PGEN, 57 versus 55 as of Nov 15, 2026. PRAX's advantage is driven primarily by stronger risk resilience and quality, while PGEN holds the stronger momentum profile. PRAX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PGEN. 2 of 5 covered evidence groups favor PRAX today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. PRAX lead: Reversed — PGEN led by 4 AIQ points 30 sessions ago; PRAX now leads by 2.

Compare Precigen, Inc. and Praxis Precision Medicines, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

PGEN
+21.1%
PRAX
+16.5%

Price return comparison

Growth of $10,000, price only

PGEN $12,107 · PRAX $11,654

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare PGEN and PRAX against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

PGEN advantage
0
PRAX advantage
  • Risk Resilience31 vs 47
    PRAX +16
  • Quality60 vs 72
    PRAX +12
  • Momentum55 vs 48
    PGEN +7

2 of 5 evidence groups favor PRAX. PRAX’s edge is concentrated in risk resilience and quality; PGEN keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

PGEN+1 AIQ

No factor moved materially.

New signals

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Keltner Channel Breakdown — bearish, volatility, short horizon
PRAX+1 AIQ

Largest factor move: Momentum +1

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.72x)

PRAX's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — PGEN and PRAX both carry a full feed there.

The central trade-off

PRAX (Praxis Precision Medicines, Inc.): the stronger current systematic profile, led by risk resilience and quality.

PGEN (Precigen, Inc.): the counter-case, on momentum, fundamentals, analyst expectations — but at materially higher volatility, 127% against 93.7%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

PRAX

PRAX on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

PGEN

PGEN on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

PGEN

PGEN on the Momentum factor, by 7 points.

Lower downside

PRAX

PRAX on Risk Resilience, by 16 points.

Analyst upside

PGEN

PGEN on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors PRAX, analyst targets favor PGEN. That disagreement is the most useful thing on this page.

MeasurePGENPRAXNote
Implied upside to target+164.3%+101.2%PGEN has more room
Target dispersion0%+19.8%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering421Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor PRAX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven55 vs 57
FundamentalsPGENEPS growth 66.7% vs -12.5%; TTM ROE 42.7% vs -7.5%
ValuationNot coveredNot covered
TechnicalsPRAXPrice vs 50-day -32.6% vs 13.2%; vs 200-day -14% vs 4.3%
Risk ResiliencePRAXRisk Resilience 31 vs 47
Analyst expectationsPGENTarget upside 164.3% vs 101.2%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PGEN and PRAX and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PRAX.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

PRAX lead: Reversed — PGEN led by 4 AIQ points 30 sessions ago; PRAX now leads by 2.

May 27PGEN leads above the line · PRAX leads belowNov 13
Today
PRAX +2
55 vs 57
7 sessions ago
PGEN +4
62 vs 58
30 sessions ago
PGEN +4
61 vs 57
90 sessions ago
PRAX +11
58 vs 69

The lead changed hands 2 times in this window, most recently on Nov 5 when PGEN moved ahead of PRAX.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

PGENConflicted

1 bullish / 2 bearish / 2 neutral, conflicted

Only PGEN

  • Golden Cross Active — bullish, trend, long horizon (27.69%)
  • Keltner Channel Breakdown — bearish, volatility, short horizon
PRAXConflicted

3 bullish / 3 bearish / 2 neutral, conflicted

Only PRAX

  • Death Cross Active — bearish, trend, long horizon (8.51%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Keltner Channel Breakout — bullish, volatility, short horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.72x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 3 more signals that do not separate them: ADX Trend Strengthening, ATR Expansion - Breakout Mode, Beta Spike Warning.

PRAX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

PGENDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.58%, AIQ +1 points).

PRAXConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.04%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PGEN closes the Risk Resilience gap — currently 16 points behind, the largest single contributor to PRAX's edge.
  2. 2PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3PRAX's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

PGEN leads on balance
MetricPGENPRAX
Revenue growth (YoY)34.9%0%
EPS growth (YoY)66.7%-12.5%
Gross margin91%0%
Operating margin21.4%0%
Return on equity (TTM)42.7%-7.5%
Debt to equity1.180

Performance

PRAX leads 5 of 6 windows
MetricPGENPRAX
1 week (5 sessions)1.6%18.2%
1 month (20 sessions)-28.9%35.7%
3 months (63 sessions)-30.7%-12.8%
6 months (126 sessions)2.7%-4.2%
Year to date8.6%11.3%
1 year (252 sessions)12.9%78.7%

Technicals

PRAX has the stronger structure
MetricPGENPRAX
RSI (14)34.261.4
ADX (14)28.823.4
Price vs 50-day-32.6%13.2%
Price vs 200-day-14%4.3%
Volatility (1M, annualized)127%93.7%

Risk

PRAX is the more resilient
MetricPGENPRAX
Beta1.621.58
Sharpe ratio0.571.13
Sortino ratio0.871.93
Max drawdown-50.7%-38.1%
Current drawdown-47%-15.1%
Annualized volatility85.4%75.1%
Value at risk (95%)-7.2%-5.5%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, PGEN or PRAX?

On the Algovestiq AIQ Score, PRAX is the stronger of the two as of Nov 15, 2026, scoring 57 against PGEN's 55. The edge comes from risk resilience and quality. PGEN is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is PGEN or PRAX the better buy right now?

PRAX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.

Why does the AIQ Score favor PRAX over PGEN?

The composite weights Quality, Value, Momentum and Risk Resilience. PRAX leads Risk Resilience by 16 points; PRAX leads Quality by 12 points; PGEN leads Momentum by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, PGEN or PRAX?

Analyst price targets imply +164.3% upside for PGEN and +101.2% for PRAX, so the Street currently favors PGEN. That points the opposite way to the AIQ Score, which favors PRAX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, PGEN or PRAX?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, PGEN or PRAX?

PGEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, PGEN or PRAX?

PGEN on the Momentum factor, by 7 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, PGEN or PRAX?

PRAX is the more resilient of the two, so the other name carries the higher downside risk. PRAX on Risk Resilience, by 16 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is PGEN more profitable than PRAX?

PGEN leads on the comparable margin measures — gross margin 91% vs 0%; operating margin 21.4% vs 0%; ttm roe 42.7% vs -7.5%.

Is PRAX's lead over PGEN getting stronger or weaker?

PRAX lead: Reversed — PGEN led by 4 AIQ points 30 sessions ago; PRAX now leads by 2. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-11-05, when PGEN moved ahead of PRAX.

What would change the PGEN vs PRAX verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PGEN closes the Risk Resilience gap — currently 16 points behind, the largest single contributor to PRAX's edge; PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PRAX's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about PGEN and PRAX?

PGEN: 1 bullish / 2 bearish / 2 neutral, conflicted. PRAX: 3 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PGEN is Golden Cross Active (bullish, long horizon). On PRAX it is Death Cross Active (bearish, long horizon).

Compare PGEN and PRAX with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.